Pembrolizumab for Prostate Cancer

"Pembrolizumab is primarily used to battle malignant neoplasms, yet it can be utilized for other ailments such as advanced melanoma, microsatellite instability-high conditions, and post-chemotherapy progression."

"As of November 8th 2022, this trial is no longer actively recruiting. Initially posted on July 1st 2015, the study has since concluded its recruitment phase. However, 5932 trials for adenocarcinoma and 961 studies involving Pembrolizumab are presently seeking participants to join their medical research."

"Currently, Pembrolizumab is the subject of 961 active trials. Out of those studies, 122 are in Phase 3. Though Houston Texas has a high number of these tests running, there are 35 731 different locations that offer this medication's clinical trial worldwide."

"The primary research goal of this trial, which will span six months or so, is to catalogue the frequency and type of adverse events with the National Cancer Common Terminology Criteria, Version 4. Secondary objectives pertain to PAP-specific T-cell Response (Number and frequencies), PAP-Specific Immune Response (quantity from immunization) , and PD-1 Expression (PD-1/PDL1 expression levels). A linear regression model or a negative binomial regression model will be utilized to evaluate effects of schedule on PD-1 expression in terms of circulating cells."

"Sadly, clinicaltrials.gov specifies that this medical trial is not currently seeking patient participants. Although the protocol was first published on July 1st 2015 and last updated on November 8th 2022, there are 6893 other studies recruiting patients presently."